Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://giantbikehelmets397743.remotelifeblog.com/312661/novo-nordisk-s-retatrutide-australia-a-potential-breakthrough-for-losing-weight